LPTX vs RCUS

Leap Therapeutics, Inc.

(LPTX) offers the better valuation at 11. 0x trailing P/E, making it the more compelling value choice. Analysts rate Arcus Biosciences, Inc. (RCUS) a "Buy" — based on 18 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Arcus Biosciences, Inc.

(RCUS) delivered a total return of -18. 6%, compared to -95. 2% for Leap Therapeutics, Inc. (LPTX). Over 10 years, the gap is even starker: RCUS returned +45. 9% versus LPTX's -99. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Arcus Biosciences, Inc.

(RCUS) is the lower-risk stock at 1. 95β versus Leap Therapeutics, Inc. 's 2. 47β — meaning LPTX is approximately 27% more volatile than RCUS relative to the S&P 500. On balance sheet safety, Leap Therapeutics, Inc. (LPTX) carries a lower debt/equity ratio of 0% versus 16% for Arcus Biosciences, Inc. — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: Leap Therapeutics, Inc.

grew EPS 103. 9% year-over-year, compared to -4. 8% for Arcus Biosciences, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Leap Therapeutics, Inc.

(LPTX) is the more profitable company, earning 73. 4% net margin versus -142. 9% for Arcus Biosciences, Inc. — meaning it keeps 73. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RCUS leads at -156. 3% versus -196. 5% for LPTX. At the gross margin level — before operating expenses — RCUS leads at 96. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Arcus Biosciences, Inc.

(RCUS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Leap Therapeutics, Inc. (LPTX) carries a higher beta of 2. 47 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (RCUS: +45. 9%, LPTX: -99. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: LPTX is a small-cap deep-value stock; RCUS is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.